Loading…
Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and G...
Saved in:
| Published in: | Journal of neurovirology 2020-10, Vol.26 (5), p.797-799 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03 |
| container_end_page | 799 |
| container_issue | 5 |
| container_start_page | 797 |
| container_title | Journal of neurovirology |
| container_volume | 26 |
| creator | Abrams, Rory M.C. Kim, Brian D. Markantone, Desiree M. Reilly, Kaitlin Paniz-Mondolfi, Alberto E. Gitman, Melissa R. Choo, S. Yoon Tse, Winona Robinson-Papp, Jessica |
| description | There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients. |
| doi_str_mv | 10.1007/s13365-020-00884-7 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7384559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2428065265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EomXgBVggL9kYrn2dxNkgwRRKpUpd8LNCspzkZuoqYw92MtI8Es_Bi-EypYINK1s6x-fc64-x5xJeSYDmdZaIdSVAgQAwRovmATuVFRqhtMaH5Y7VrWz0CXuS8w2AxFqZx-wEVaNAIZ6yb59oT4l4cjs_TAe-S3GTKGe_J36--GlyPoh3LqWfP3g-hCHFLXEf-HxNPNM8-7DhceSuX2bi66uvF2dCtnzwmVymp-zR6KZMz-7OFfvy4f3n9UdxeXV-sX57KXqt61l0uu2GCrGDauxQt0ph3WlwY6Oo7hvlgEw9yqYdVdNqMj0AonPSDR0pOQKu2Jtj7m7ptjT0FObkJrtLfuvSwUbn7b9K8Nd2E_e2QaOrqi0BL-8CUvy-UJ7t1ueeyvaB4pKt0spAXam6KlZ1tPYp5pxovK-RYG-x2CMWW7DY31hKy4q9-HvA-yd_OBQDHg25SGFDyd7EJYXyaf-L_QXUlJnc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2428065265</pqid></control><display><type>article</type><title>Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease</title><source>Springer Nature</source><creator>Abrams, Rory M.C. ; Kim, Brian D. ; Markantone, Desiree M. ; Reilly, Kaitlin ; Paniz-Mondolfi, Alberto E. ; Gitman, Melissa R. ; Choo, S. Yoon ; Tse, Winona ; Robinson-Papp, Jessica</creator><creatorcontrib>Abrams, Rory M.C. ; Kim, Brian D. ; Markantone, Desiree M. ; Reilly, Kaitlin ; Paniz-Mondolfi, Alberto E. ; Gitman, Melissa R. ; Choo, S. Yoon ; Tse, Winona ; Robinson-Papp, Jessica</creatorcontrib><description>There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.</description><identifier>ISSN: 1355-0284</identifier><identifier>EISSN: 1538-2443</identifier><identifier>DOI: 10.1007/s13365-020-00884-7</identifier><identifier>PMID: 32720233</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Acute Disease ; Aged ; Anticoagulants - therapeutic use ; Betacoronavirus - pathogenicity ; Biomedical and Life Sciences ; Biomedicine ; Case Report ; Coronavirus Infections - complications ; Coronavirus Infections - pathology ; Coronavirus Infections - therapy ; Coronavirus Infections - virology ; COVID-19 ; Disease Progression ; Enoxaparin - therapeutic use ; Female ; Guillain-Barre Syndrome - complications ; Guillain-Barre Syndrome - pathology ; Guillain-Barre Syndrome - therapy ; Guillain-Barre Syndrome - virology ; Humans ; Hyponatremia - complications ; Hyponatremia - pathology ; Hyponatremia - therapy ; Hyponatremia - virology ; Immunology ; Infectious Diseases ; Neurology ; Neurosciences ; New York City ; Pandemics ; Plasmapheresis ; Pneumonia, Viral - complications ; Pneumonia, Viral - pathology ; Pneumonia, Viral - therapy ; Pneumonia, Viral - virology ; SARS-CoV-2 ; Virology</subject><ispartof>Journal of neurovirology, 2020-10, Vol.26 (5), p.797-799</ispartof><rights>Journal of NeuroVirology, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03</citedby><cites>FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03</cites><orcidid>0000-0002-9675-4012</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32720233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abrams, Rory M.C.</creatorcontrib><creatorcontrib>Kim, Brian D.</creatorcontrib><creatorcontrib>Markantone, Desiree M.</creatorcontrib><creatorcontrib>Reilly, Kaitlin</creatorcontrib><creatorcontrib>Paniz-Mondolfi, Alberto E.</creatorcontrib><creatorcontrib>Gitman, Melissa R.</creatorcontrib><creatorcontrib>Choo, S. Yoon</creatorcontrib><creatorcontrib>Tse, Winona</creatorcontrib><creatorcontrib>Robinson-Papp, Jessica</creatorcontrib><title>Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease</title><title>Journal of neurovirology</title><addtitle>J. Neurovirol</addtitle><addtitle>J Neurovirol</addtitle><description>There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.</description><subject>Acute Disease</subject><subject>Aged</subject><subject>Anticoagulants - therapeutic use</subject><subject>Betacoronavirus - pathogenicity</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Case Report</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - pathology</subject><subject>Coronavirus Infections - therapy</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>Disease Progression</subject><subject>Enoxaparin - therapeutic use</subject><subject>Female</subject><subject>Guillain-Barre Syndrome - complications</subject><subject>Guillain-Barre Syndrome - pathology</subject><subject>Guillain-Barre Syndrome - therapy</subject><subject>Guillain-Barre Syndrome - virology</subject><subject>Humans</subject><subject>Hyponatremia - complications</subject><subject>Hyponatremia - pathology</subject><subject>Hyponatremia - therapy</subject><subject>Hyponatremia - virology</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>New York City</subject><subject>Pandemics</subject><subject>Plasmapheresis</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - pathology</subject><subject>Pneumonia, Viral - therapy</subject><subject>Pneumonia, Viral - virology</subject><subject>SARS-CoV-2</subject><subject>Virology</subject><issn>1355-0284</issn><issn>1538-2443</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhS0EomXgBVggL9kYrn2dxNkgwRRKpUpd8LNCspzkZuoqYw92MtI8Es_Bi-EypYINK1s6x-fc64-x5xJeSYDmdZaIdSVAgQAwRovmATuVFRqhtMaH5Y7VrWz0CXuS8w2AxFqZx-wEVaNAIZ6yb59oT4l4cjs_TAe-S3GTKGe_J36--GlyPoh3LqWfP3g-hCHFLXEf-HxNPNM8-7DhceSuX2bi66uvF2dCtnzwmVymp-zR6KZMz-7OFfvy4f3n9UdxeXV-sX57KXqt61l0uu2GCrGDauxQt0ph3WlwY6Oo7hvlgEw9yqYdVdNqMj0AonPSDR0pOQKu2Jtj7m7ptjT0FObkJrtLfuvSwUbn7b9K8Nd2E_e2QaOrqi0BL-8CUvy-UJ7t1ueeyvaB4pKt0spAXam6KlZ1tPYp5pxovK-RYG-x2CMWW7DY31hKy4q9-HvA-yd_OBQDHg25SGFDyd7EJYXyaf-L_QXUlJnc</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Abrams, Rory M.C.</creator><creator>Kim, Brian D.</creator><creator>Markantone, Desiree M.</creator><creator>Reilly, Kaitlin</creator><creator>Paniz-Mondolfi, Alberto E.</creator><creator>Gitman, Melissa R.</creator><creator>Choo, S. Yoon</creator><creator>Tse, Winona</creator><creator>Robinson-Papp, Jessica</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9675-4012</orcidid></search><sort><creationdate>20201001</creationdate><title>Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease</title><author>Abrams, Rory M.C. ; Kim, Brian D. ; Markantone, Desiree M. ; Reilly, Kaitlin ; Paniz-Mondolfi, Alberto E. ; Gitman, Melissa R. ; Choo, S. Yoon ; Tse, Winona ; Robinson-Papp, Jessica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute Disease</topic><topic>Aged</topic><topic>Anticoagulants - therapeutic use</topic><topic>Betacoronavirus - pathogenicity</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Case Report</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - pathology</topic><topic>Coronavirus Infections - therapy</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>Disease Progression</topic><topic>Enoxaparin - therapeutic use</topic><topic>Female</topic><topic>Guillain-Barre Syndrome - complications</topic><topic>Guillain-Barre Syndrome - pathology</topic><topic>Guillain-Barre Syndrome - therapy</topic><topic>Guillain-Barre Syndrome - virology</topic><topic>Humans</topic><topic>Hyponatremia - complications</topic><topic>Hyponatremia - pathology</topic><topic>Hyponatremia - therapy</topic><topic>Hyponatremia - virology</topic><topic>Immunology</topic><topic>Infectious Diseases</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>New York City</topic><topic>Pandemics</topic><topic>Plasmapheresis</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - pathology</topic><topic>Pneumonia, Viral - therapy</topic><topic>Pneumonia, Viral - virology</topic><topic>SARS-CoV-2</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abrams, Rory M.C.</creatorcontrib><creatorcontrib>Kim, Brian D.</creatorcontrib><creatorcontrib>Markantone, Desiree M.</creatorcontrib><creatorcontrib>Reilly, Kaitlin</creatorcontrib><creatorcontrib>Paniz-Mondolfi, Alberto E.</creatorcontrib><creatorcontrib>Gitman, Melissa R.</creatorcontrib><creatorcontrib>Choo, S. Yoon</creatorcontrib><creatorcontrib>Tse, Winona</creatorcontrib><creatorcontrib>Robinson-Papp, Jessica</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neurovirology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abrams, Rory M.C.</au><au>Kim, Brian D.</au><au>Markantone, Desiree M.</au><au>Reilly, Kaitlin</au><au>Paniz-Mondolfi, Alberto E.</au><au>Gitman, Melissa R.</au><au>Choo, S. Yoon</au><au>Tse, Winona</au><au>Robinson-Papp, Jessica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease</atitle><jtitle>Journal of neurovirology</jtitle><stitle>J. Neurovirol</stitle><addtitle>J Neurovirol</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>26</volume><issue>5</issue><spage>797</spage><epage>799</epage><pages>797-799</pages><issn>1355-0284</issn><eissn>1538-2443</eissn><abstract>There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32720233</pmid><doi>10.1007/s13365-020-00884-7</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-9675-4012</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-0284 |
| ispartof | Journal of neurovirology, 2020-10, Vol.26 (5), p.797-799 |
| issn | 1355-0284 1538-2443 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7384559 |
| source | Springer Nature |
| subjects | Acute Disease Aged Anticoagulants - therapeutic use Betacoronavirus - pathogenicity Biomedical and Life Sciences Biomedicine Case Report Coronavirus Infections - complications Coronavirus Infections - pathology Coronavirus Infections - therapy Coronavirus Infections - virology COVID-19 Disease Progression Enoxaparin - therapeutic use Female Guillain-Barre Syndrome - complications Guillain-Barre Syndrome - pathology Guillain-Barre Syndrome - therapy Guillain-Barre Syndrome - virology Humans Hyponatremia - complications Hyponatremia - pathology Hyponatremia - therapy Hyponatremia - virology Immunology Infectious Diseases Neurology Neurosciences New York City Pandemics Plasmapheresis Pneumonia, Viral - complications Pneumonia, Viral - pathology Pneumonia, Viral - therapy Pneumonia, Viral - virology SARS-CoV-2 Virology |
| title | Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T01%3A51%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20rapidly%20progressive%20Guillain-Barr%C3%A9%20syndrome%20in%20the%20setting%20of%20acute%20COVID-19%20disease&rft.jtitle=Journal%20of%20neurovirology&rft.au=Abrams,%20Rory%20M.C.&rft.date=2020-10-01&rft.volume=26&rft.issue=5&rft.spage=797&rft.epage=799&rft.pages=797-799&rft.issn=1355-0284&rft.eissn=1538-2443&rft_id=info:doi/10.1007/s13365-020-00884-7&rft_dat=%3Cproquest_pubme%3E2428065265%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-b49bd533b05fb3492236b40af72e6c72a0e86f179f2794e8c0033aa1adbe21f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2428065265&rft_id=info:pmid/32720233&rfr_iscdi=true |